# Novavax share price today (Novavax, Inc., NVAX)

> Novavax, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. NVAX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/nvax

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $9.78 (+31.5% in a year)
- Revenue (Jun 2026): ₹0.1 B (−76.3% on a year ago)
- Profit (Jun 2026): −₹0.1 B (−150.1% on a year ago)
- Operating margin: −89.6% (−133.8 points on a year ago)

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Novavax share price today? Novavax, Inc.'s share price was $9.78 at the close on 5 November 2026. That is 4.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $13, and at that close it sat 53% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 10 weeks in a row. Over the last 1 year the share price moved +43% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Novavax pay? Novavax, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Novavax on? Novavax is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Novavax profitable? Novavax, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. Full-year FY25 profit was ₹0.4 B. That loss is 94.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.1 B. 8 of the last 12 reported quarters were loss-making. Jun 2026 profit was −₹0.1 B, −150.1% on a year earlier. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Novavax make, and is it growing? Novavax, Inc. reported ₹0.1 B of revenue in the Jun 2026 quarter, −76.3% on the same quarter a year earlier. Over 4 years it has grown −0.5% a year on average. The last full year, FY25, came in at ₹1.1 B. The last four reported quarters add to ₹0.4 B. FY25 revenue was ₹1.1 B, +64.7% on the year before. Recent pace: the last four quarters grew −26.4% on average, against −0.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −61.6%, against −35.3% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Novavax keep? Novavax, Inc.'s operating margin was −89.6% in the Jun 2026 quarter, 133.8 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −147.1% and 50.1%. The latest quarter is within that range. Across 5 years it has been between −147.1% and 50.1%, and FY25's 50.1% is the highest of them. Why the margin moved: operating margin changed −133.8 percentage points on the year while gross margin changed −93.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Novavax's profit turning into cash? Novavax, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.2 B of cash, against ₹0.4 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.3 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Novavax's cash go? Novavax, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Novavax's P/E ratio, and how does it compare with its own history? Novavax, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Novavax business getting better or worse? Novavax, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Novavax earn on its capital? Novavax, Inc. earned a ROE of −345% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −577%, a number that says nothing useful about the business. It comes from a 39.2% net margin and 0.95× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 39.2% net margin × 0.95× asset turnover × −9.21× leverage (assets divided by equity) ≈ −343.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Novavax have too much debt? Novavax, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −1.49 in FY21 to −2.18 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Novavax shareholding pattern? 32.4% of Novavax, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Novavax from balance-sheet trouble? For Novavax, Inc., the Z-score is −5.50. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −5.50 is inside the danger zone, so the balance sheet is a real risk. ## How does Novavax rank in its industry? There is no score against its industry: Novavax, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Novavax compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Novavax in size? Novavax is the 87th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Agios Pharmaceuticals, Inc., Nurix Therapeutics, Inc. and Generate Biomedicines, Inc. Just below it: Absci Corporation, Ultragenyx Pharmaceutical Inc. and Nanobiotix S.A. ### Biotechnology companies close in size

1. [Agios Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/agio) $1.7 billion
2. [Nurix Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/nrix) $1.6 billion
3. [Generate Biomedicines, Inc.](https://www.sectoralpha.in/us/stocks/genb) $1.6 billion
4. Novavax, Inc. $1.6 billion
5. [Absci Corporation](https://www.sectoralpha.in/us/stocks/absi) $1.6 billion
6. [Ultragenyx Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/rare) $1.6 billion
7. [Nanobiotix S.A.](https://www.sectoralpha.in/us/stocks/nbtx) $1.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Werner Enterprises, Inc.](https://www.sectoralpha.in/us/stocks/wern) $1.8 billion · Trucking
2. [Flowco Holdings Inc.](https://www.sectoralpha.in/us/stocks/floc) $1.8 billion · Oil & Gas Equipment & Services
3. Novavax, Inc. $1.8 billion
4. [ChronoScale Holdings Corporation](https://www.sectoralpha.in/us/stocks/chrn) $1.8 billion · Information Technology Services
5. [Alamo Group Inc.](https://www.sectoralpha.in/us/stocks/alg) $1.8 billion · Farm & Heavy Construction Machinery

## What else do people ask about Novavax? ### What were Novavax's latest quarterly results? Novavax, Inc. reported revenue of ₹0.1 B and a net loss of ₹0.1 B for the Jun 2026 quarter. Revenue fell 76.3% and profit fell 150.1% compared with a year earlier. The operating margin was −89.6%, 133.8 percentage points lower than a year earlier (as of 5 November 2026). ### What is Novavax's market cap? Novavax, Inc.'s market capitalisation is $1.6 B at a stock price of $9.78. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Novavax performing? Novavax, Inc.'s latest readings are below. In its latest quarter, revenue fell 76.3% and profit fell 150.1% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 10 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Novavax's stock price go up? This page does not forecast Novavax, Inc.'s stock price. What it shows instead: the stock price is $9.78. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Novavax in its business cycle? Novavax, Inc.'s FY25 operating margin was 50.1%, against a 5-year range of −147.1% to 50.1%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was −89.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Novavax story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Novavax a stock worth studying right now? What the numbers show: Novavax, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.